TREM2 is thyroid hormone regulated making the TREM2 pathway druggable with ligands for thyroid hormone receptor

Autor: Priya Chaudhary, Thomas S. Scanlan, Edvinas Pocius, Brooke A. Napier, Gail Marracci, Hannah Miller, Skylar J. Ferrara, Evan Calkins, Dennis Bourdette, Margaret J. DeBell, Ben Emery
Rok vydání: 2022
Předmět:
Models
Molecular

Protein Conformation
alpha-Helical

Clinical Biochemistry
Acetates
Phenoxyacetates
Biochemistry
Mice
Drug Discovery
Sobetirome
Receptors
Immunologic

Promoter Regions
Genetic

Receptor
Membrane Glycoproteins
Microglia
Experimental autoimmune encephalomyelitis
Thyroid
Brain
medicine.anatomical_structure
Molecular Medicine
Signal transduction
Protein Binding
Signal Transduction
Thyroid Hormones
Encephalomyelitis
Autoimmune
Experimental

Biology
Response Elements
Article
Phenols
medicine
Animals
Humans
Protein Interaction Domains and Motifs
RNA
Messenger

Molecular Biology
Pharmacology
Binding Sites
Thyroid hormone receptor
Innate immune system
business.industry
TREM2
Macrophages
medicine.disease
Immunity
Innate

Mice
Inbred C57BL

Retinoid X Receptors
Gene Expression Regulation
Cancer research
Protein Conformation
beta-Strand

business
Hormone
Zdroj: Cell Chem Biol
bioRxiv
ISSN: 2451-9456
DOI: 10.1016/j.chembiol.2021.07.014
Popis: Triggering receptor expressed on myeloid cells-2 (TREM2) is a cell surface receptor on macrophages and microglia that senses and responds to disease associated signals to regulate the phenotype of these innate immune cells. The TREM2 signaling pathway has been implicated in a variety of diseases ranging from neurodegeneration in the central nervous system to metabolic disease in the periphery. We report here that TREM2 is a thyroid hormone regulated gene and its expression in macrophages and microglia is stimulated by thyroid hormone. Both endogenous thyroid hormone and sobetirome, a synthetic thyroid hormone agonist drug, suppress pro-inflammatory cytokine production from myeloid cells including macrophages that have been treated with the SARS-CoV-2 spike protein which produces a strong, pro-inflammatory phenotype. Thyroid hormone agonism was also found to induce phagocytic behavior in microglia, a phenotype consistent with activation of the TREM2 pathway. The thyroid hormone antagonist NH-3 blocks the anti-inflammatory effects of thyroid hormone agonists and suppresses microglia phagocytosis. Finally, in a murine experimental autoimmune encephalomyelitis (EAE) multiple sclerosis model, treatment with Sob-AM2, a CNS-penetrating sobetirome prodrug, results in increased Trem2 expression in disease lesion resident myeloid cells which correlates with therapeutic benefit in the EAE clinical score and reduced damage to myelin. Our findings represent the first report of endocrine regulation of TREM2 and provide a unique opportunity to drug the TREM2 signaling pathway with orally active small molecule therapeutic agents.
Databáze: OpenAIRE